CathWorks
About CathWorks
CathWorks is a medical technology company dedicated to transforming the diagnosis and treatment of coronary artery disease (CAD) by providing physicians with advanced computational science tools. Their flagship product, the FFRangio System, leverages artificial intelligence (AI) and sophisticated computational fluid dynamics to generate objective, wire-free physiological information directly from routine angiograms. This innovative approach aims to elevate coronary angiography from a visual assessment to a precise, FFR-based decision-making tool.
The FFRangio System processes standard angiogram images to create comprehensive physiological data, including color-coded 3D renderings of blood flow within the coronary arteries. This enables interventional cardiologists to optimize treatment decisions, such as determining the necessity of a stent, without the need for invasive pressure wires or pharmacologic stimulation. The system provides real-time fractional flow reserve (FFR) values across the entire coronary tree, simulated pullback curves to identify functional patterns of CAD, and integrated sizing tools for non-invasive lesion measurements.
By eliminating the invasive aspects of traditional FFR measurements, CathWorks’ technology offers a quicker, more comfortable, and comprehensive assessment for patients, while streamlining workflow in the cath lab. Clinical evidence has demonstrated its high diagnostic accuracy and promising clinical outcomes when compared to conventional wire-based FFR.
Focus Areas
Business Intelligence
| Key Investors | Medtronic, Deerfield Management, Abiomed, Innovation Authority, Ministry of Economy and Industry, Pura Vida Investments, Triventures, Corundum Open Innovation, Pontifax, BioStar Ventures, Quark Venture, Planven |
| Partnerships | Medtronic (co-promotion and acquisition), AdventHealth, Hackensack Meridian Mountainside Medical Center, Lenox Hill Hospital, T.J. Samson Hospital |
| Acquisitions | Acquired by Medtronic (pending FTC clearance, announced February 2026) |
| Technology | AI and advanced computational science, angiography-derived FFR computation, computational hemodynamic simulation, 3D reconstruction and visualization of coronary arteries, computer vision for angiographic image analysis, medical device software platforms |
| FDA Clearances | 1 cleared products (estimated) |
What Physicians Need to Know
For physicians, CathWorks' FFRangio System offers a less invasive, wire-free, and drug-free approach to FFR assessment, significantly streamlining procedural workflow in the cath lab. The system provides real-time, comprehensive, multi-vessel FFR values and advanced PCI planning tools (simulated pullback, lesion impact, integrated sizing) to optimize clinical decision-making with scientific certainty, moving beyond visual estimation. This leads to reduced procedure time, radiation exposure, and contrast use, enhancing both patient comfort and safety. Clinical trials have demonstrated high diagnostic accuracy and comparable one-year major adverse cardiac event (MACE) rates to invasive FFR, reinforcing its value for evidence-based treatment.
The CathWorks FFRangio System is designed for seamless integration with existing cath lab infrastructure, including the boom and PACS (Picture Archiving and Communication System). It analyzes routine DICOM angiography data, ensuring compatibility with standard medical imaging workflows. This integration minimizes disruption and allows for efficient, parallel processing of physiological assessments during ongoing procedures.
What the Web Says
CathWorks is a company focused on optimizing care for patients with coronary artery disease through its FFRangio System. The system uses AI and advanced computational science to provide non-invasive, wire-free 3D FFR guidance from routine angiograms, aiming to improve treatment decisions and streamline workflow. While product reviews are largely positive, highlighting its diagnostic accuracy and clinical outcomes, employee reviews on platforms like Indeed suggest mixed sentiments regarding company culture, management, and work-life balance.
Overall: MixedStrengths
- High diagnostic accuracy (consistently 92-97%) compared to wire-based FFR.
- Non-invasive, eliminating the need for pressure wires, hyperemic agents, and guide catheters.
- Provides comprehensive multi-vessel coronary physiology and PCI planning tools.
- Reduces radiation exposure by approximately 20% compared to wire-based physiology.
- Streamlines procedural workflow with an intuitive user interface and AI-aided analysis.
- Comparable one-year major adverse cardiac event (MACE) rates to invasive FFR.
Limitations
- Mixed employee reviews regarding work-life balance, pay, and benefits.
- Negative feedback on management and job security/advancement from employees.
- Some employee reviews mention unfair pay and inexperienced staff.
- Diagnostic performance not established for lesions immediately after PCI.
- The use of FFRangio may not be appropriate for all patients, particularly those with STEMI, impaired ejection fraction, severe diffuse disease, dilated coronary vessels, moderate or severe aortic stenosis, or a history of selected prior heart surgeries.
- Limited advancement opportunities cited by some employees.
Based on reviews from: Indeed.com, PR Newswire, YouTube, Medtronic, accessdata.fda.gov, Medical Device and Diagnostic industry, Reddit
Last updated: 2026-07-17
Videos
News, demos, and interviews about CathWorks.
Videos load interactively. If none appear, search YouTube for CathWorks →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded CathWorks.
Related Companies
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]